The 5 analysts offering 12-month price forecasts for Homology Medicines Inc have a median target of 35.00, with a high estimate of 37.00 and a low estimate of 29.00. The median estimate represents a +101.85% increase from the last price of 17.34.
The current consensus among 7 polled investment analysts is to Buy stock in Homology Medicines Inc. This rating has held steady since December, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.68
Reporting Date Mar 17
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.